Emergence of nonvaccine serotypes following introduction of pneumococcal conjugate vaccine: cause and effect?
Moore
Matthew R
MR
Respiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. matt.moore@cdc.hhs.gov
Whitney
Cynthia G
CG
D002648:Child; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D022401:Meningococcal Vaccines / Q000276:immunology / Q000627:therapeutic use*; D011008:Pneumococcal Infections / Q000453:epidemiology* / Q000382:microbiology* / Q000517:prevention & control; D022242:Pneumococcal Vaccines / Q000276:immunology / Q000627:therapeutic use*; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000276:immunology*
D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022401:Meningococcal Vaccines; D022242:Pneumococcal Vaccines